Acanthoma

Summary

Acanthoma (MONDO:0002093) is a disease (an umbrella term covering 6 Mondo subtypes). A subtype of benign epithelial skin neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acanthoma
Mondo ID	MONDO:0002093
MeSH	D049309
DOID	DOID:174
NCIT	C7419
UMLS	C0846967
MedGen	208851
Is cancer (heuristic)	no

Also known as: acanthoma · acanthoma (disease)

Data availability: 1 HPO phenotype.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system benign neoplasm › benign neoplasm of skin › benign epithelial skin neoplasm › acanthoma

Related subtypes (7): common wart, plantar wart, vulvar nodular hidradenoma, skin papilloma, breast apocrine adenoma, trichoblastoma, syringofibroadenoma

Subtypes (6): clear cell acanthoma, large cell acanthoma, epidermolytic acanthoma, acantholytic acanthoma, pilar sheath acanthoma, warty dyskeratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.